Production of YP170 Vitellogenins Promotes Intestinal Senescence in Caenorhabditis elegans

Thanet Sornda, MRes,1,2 Marina Ezcurra, PhD,1,3 Carina Kern, BSc,1 Evgeniy R. Galimov, PhD,1 Catherine Au, MSc,1 Yila de la Guardia, PhD,1,4 and David Gems, PhD,1,*

1Institute of Healthy Ageing, Research Department of Genetics, Evolution and Environment, University College London, UK. 2Department of Biochemistry, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand. 3School of Biosciences, University of Kent, Canterbury, UK. 4Instituto de Investigaciones Científicas y Servicios de Alta Tecnología, Ciudad del Saber, Panama.

*Address correspondence to: David Gems, PhD, Institute of Healthy Ageing, Research Department of Genetics, Evolution and Environment, University College London, London WC1E 6BT, UK. E-mail: david.gems@ucl.ac.uk

Received: December 6, 2018; Editorial Decision Date: February 28, 2019

Decision Editor: David Le Couteur, MBBS, FRACP, PhD

Abstract

During aging, etiologies of senescence cause multiple pathologies, leading to morbidity and death. To understand aging requires identification of these etiologies. For example, Caenorhabditis elegans hermaphrodites consume their own intestinal biomass to support yolk production, which in later life drives intestinal atrophy and ectopic yolk deposition. Yolk proteins (YPs; vitellogenins) exist as three abundant species: YP170, derived from vit-1–vit-5; and YP115 and YP88, derived from vit-6. Here, we show that inhibiting YP170 synthesis leads to a reciprocal increase in YP115/YP88 levels and vice versa, an effect involving posttranscriptional mechanisms. Inhibiting YP170 production alone, despite increasing YP115/YP88 synthesis, reduces intestinal atrophy as much as inhibition of all YP synthesis, which increases life span. By contrast, inhibiting YP115/YP88 production alone accelerates intestinal atrophy and reduces life span, an effect that is dependent on increased YP170 production. Thus, despite copious abundance of both YP170 and YP115/YP88, only YP170 production is coupled to intestinal atrophy and shortened life span. In addition, increasing levels of YP115/YP88 but not of YP170 increases resistance to oxidative stress; thus, longevity resulting from reduced vitellogenin synthesis is not attributable to oxidative stress resistance.

Keywords: Aging, Age-related pathology, Animal model, Caenorhabditis elegans, Yolk

The mechanisms underlying the aging process remain poorly defined. According to the hyper-function theory (1–4), one contributory mechanism is futile run-on in later life of developmental and reproductive programs (or quasi-programs), leading to the development of senescent pathologies, including some that limit life span. One way of viewing aging (ie, senescence) is as the set of pathologies that increase in later life (5). This suggests that to understand the causes of aging, including in model organisms such as Caenorhabditis elegans, one needs to characterize late-life pathologies and then discover their origins. Where pathologies result from quasi-programs, this requires identifying the biological programs whose run-on generates them.

Aging C. elegans exhibits a number of pathologies that are potentially attributable to run-on (6). One such is a steatotic accumulation of yolky lipid, mainly in the body cavity in the form of large oily pools but also in muscles and uterine tumors (7–10). This appears to result from seemingly futile run-on of yolk synthesis in later life. Earlier in adulthood, during hermaphrodite reproduction, developing oocytes are provisioned with yolk, which is lipoprotein that contains several vitellogenin proteins, products of the genes vit-1–vit-6. Yolk provisioning is assumed to promote larval fitness, although knockdown of yolk production has little effect on progeny production under standard laboratory culture conditions (11). The C. elegans vitellogenin (VIT) proteins contain domains homologous to the apoprotein of human low-density lipoprotein, apoB-100 (12,13). In C. elegans, yolk proteins (YPs) bind and transport lipids such as triglycerides and cholesterol to oocytes, thereby showing a similar function to low-density lipoprotein in mammals (14). Vitellogenin precursors are synthesized in the intestine and then secreted into the pseudocoelom (body cavity), from which yolk is taken up by developing oocytes by endocytosis via the low-density lipoprotein-like receptor RME-2 (15,16).
On electrophoretic gels, four YP bands are visible: the closely running YP170A and YP170B, encoded by vit-3 to -5 and vit-1, -2, respectively, and YP115 and YP88, encoded by vit-6 (17). vit-6 initially generates a precursor, YP180, which after leaving the intestine and before being taken up by oocytes is cleaved. vit-3 and -4 have more than 99% sequence similarity to each other and 96% sequence similarity to vit-5, and vit-3, -4, -5 are 68% similar to vit-1, -2, whereas vit-6 is 50% similar to the other vit genes (17). vit-1 was at first thought to be a pseudogene, but sequencing of the *C. elegans* genome showed that this is not so (18,19).

*C. elegans* hermaphrodites initially produce sperm but then switch to production of oocytes, which are fertilized by self-sperm. On depletion of self-sperm after 3–4 days, reproduction ceases, but after this vitellogenesis continues and yolk accumulates to high levels in the body cavity (7,8,10,20), with YP170 levels increasing approximately sixfold between day 1 and day 8 of adulthood (10,21). This suggests that *C. elegans* hermaphrodites lack a mechanism to switch off yolk production after sperm depletion, that is, that there exists what is effectively a vitellogenic open faucet (8,10,22).

Yolk synthesis occurs in the intestine, which in *C. elegans* is the main metabolic organ, also performing the functions of liver and adipose tissue, and is a major site of action of genes with effects on life span (23,24). The intestine also exhibits major senescent pathology, most notably severe atrophy, including loss of nuclei and microvilli (10,20). We recently identified a mechanism causing intestinal atrophy, demonstrating that yolk synthesis is coupled to intestinal atrophy, as gut biomass is apparently consumed to sustain yolk synthesis (10). Gut-to-yolk biomass conversion is mediated by autophagy and promoted by insulin/insulin-like growth factor 1 (IGF-1) signaling, and several interventions that reduce intestinal atrophy also increase life span (10).

In this study, we verify the vitellogenic open faucet model, showing that yolk accumulation results from a relatively steady flow of continued synthesis of yolk during adulthood combined with cessation of egg laying. We also describe how blocking YP115/YP88 synthesis increases YP170 levels, which accelerates gut atrophy and shortens life span; thus, it is YP170 production specifically that is a major driver of *C. elegans* senescence. In addition, increased YP115/YP88 level protects against oxidative stress but does not increase life span, suggesting that life span is not limited by oxidative stress. These findings are broadly consistent with the hyper-function theory (1–4).

**Methods**

**Culture Methods and Strains**

*Caenorhabditis elegans* were maintained using standard conditions (23), at 20°C on nematode growth medium (NGM) plates seeded with *Escherichia coli* OP50, or HT115 for RNA interference (RNAi), performed as described previously (26). RNAi trials were initiated from egg hatching, unless otherwise stated. The following strains were used: N2 hermaphrodite stock (27), DH26 rf-3(b26) II (formerly fer-15), EG3234 oxIs144 [inx-16p::inx-16::GFP, lin-15+], GA504 wuls54 [ppDD95,77 sod-1p::sod-1::GFP, rol-6(su1006)] (28), GA631 wuls177 [ftn-1p::GFP, lin-15+](29), JK574 fog-2(q71) V, and LD1171 lds3 [gcs-1p::GFP + rol-6(su1006)].

**Mating Protocol**

*fog-2(q71)* or *rf-3(b26)* males were used for mating tests. Animals were picked at the L4 stage and added to NGM plates at a ratio of 3:1 males to hermaphrodites or females and left to mature and mate for 24 hours, after which males were removed. *rf-3* males were raised and mated at 23°C, the nonpermissive temperature for the *rf-3(b26)* fertilization defective (Fer) phenotype; after removal of *rf-3* males, fog-2 females were shifted to 20°C.

**Nematode Protein Content Measurements**

Total protein was measured using bicinchoninic acid. One hundred worms were harvested into 50 μL of M9 buffer and frozen at –80°C until used. Samples were added with 250 μL of CellLytic M buffer (Sigma-Aldrich) containing 1:1,000 protease inhibitor cocktails, sonicated with a Bioruptor (Cosmo Bio Co., Ltd) for 8 minutes with 30-second intervals and centrifuged at 4°C at 6,000 rpm for 15 minutes. The bicinchoninic acid procedure was performed using 96-well plates. For each well, 200 μL testing solution was mixed with 25 μL sample or bovine serum albumin standards. The plate was mixed gently, incubated at room temperature for 2 minutes, and incubated at 37°C for 30 minutes. The plate was measured for absorbance at 620 nm.

**YP Measurements**

Yolk levels were quantified by Coomassie blue staining. Twenty worms were harvested into 25 μL of M9 buffer and frozen at –80°C until used. Samples were added with 25 μL of 2x Laemmli sample buffer (Sigma-Aldrich), incubated at 70°C and vortexed periodically for 15 minutes, and then incubated at 95°C for 5 minutes and centrifuged at 6,000 rpm for 15 minutes. Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) was performed, using Criterion XT Precast Gels 4–12% Bis-Tris (Bio-Rad) and XT MOPS (Bio-Rad) as a running buffer. Gels were stained with Coomassie blue following standard protocols. Gels were analyzed using ImageQuant LAS 4000 (GE Healthcare). Protein band identification was based on published data (21). YPs were normalized to myosin and the ratio of actin to myosin was used to give an indication of the reliability of myosin as a standard.

**Microscopy**

Worms were mounted onto 2% agar pads and anesthetized with 0.2% levamisole, and coverslips were gently placed onto the pads. Nomarski images of worms were acquired using a Zeiss microscope with a Hamamatsu ORCA-ER digital camera C4742-95 using Volocity software, version 6.3 (Improvision, Perkin-Elmer). For fluorescence images, a fluorescein isothiocyanate (FITC)/green fluorescent protein (GFP) filter cube (excitation range 450–490 nm, emission range 515–565 nm) was used. A constant exposure time was maintained between samples in fluorescence intensity comparisons.

**Intestinal Atrophy and Yolk Pool Accumulation Measurements**

Intestinal atrophy and yolk pool accumulation were measured as described previously, using Nomarski microscopy (10). Intestinal atrophy was quantified by measuring the intestinal width at the mid-part of the posterior intestine, subtracting the lumen width and dividing by the body width (10). Yolk pool accumulation was quantified by measuring total yolk pool area and dividing by body area (10).

**RNA Isolation and Quantitative Polymerase Chain Reaction**

Approximately 150 worms were collected in 50 μL of M9, to which 800 μL Trizol (Sigma-Aldrich) was rapidly added, and samples were
then stored at –80°C until processing. Complementary DNA was synthesized using the SuperScript IV Reverse Transcriptase (Invitrogen). SYBR Green Real-Time PCR was performed using a QuantStudio 6 Flex Real-Time PCR System (Thermo Fisher Scientific) and normalized using the ΔΔCt method as described previously (30).

Life-span Assays
Animals were maintained at 20–25 worms per plate. Life spans were scored every day or every other day for dead worms, starting from day 1 of adulthood. Raw mortality data for all trials are provided (Supplementary Dataset 2).

Oxidative Stress Resistance Assays
L4 stage worms were transferred to plates containing 40 mM paraquat (Sigma-Aldrich) or 7.5 mM tert-butyl hydroperoxide (t-BOOH; Sigma-Aldrich). These plates had been seeded with HT115 bearing RNAi plasmids for 2 days. Animals were incubated at 20°C and, from day 1 of adulthood, scored for survival daily or hourly for paraquat or t-BOOH, respectively. Raw mortality data for all trials are provided (Supplementary Dataset 2).

Statistical Analysis
The Student’s t test was used. One-way analysis of variance was performed for multiple comparisons, and Tukey-Kramer multiple comparison was used to obtain statistical comparisons between all groups. For survival assays, statistical significance was estimated using log-rank and Wilcoxon tests using JMP software, version 13.0 (SAS Institute, Inc.). Graphs display mean values and all error bars depict standard error of the mean.

Results
A Vitellogenic Open Faucet Contributes to Yolk Accumulation
A working hypothesis is that continued vitellogenesis after sperm depletion promotes visceral pathology in C. elegans hermaphrodites. According to this view, yolk accumulation is a function of (a) una- bated yolk production in adult hermaphrodites, and (b) a decline in egg laying. This model is analogous to an open faucet filling a sink: the content of the sink reflects the rate of flow of the faucet (cf. yolk synthesis) and the presence or absence of an open plug hole (cf. egg laying; Figure 1A).

An open faucet mechanism predicts a steady rate of YP accumulation after the cessation of egg laying. To test this, we examined how the rate of vitellogenin accumulation changes with increasing age in selfed wild-type hermaphrodites, by reanalyzing previously reported YP accumulation data (10). Age changes in yolk accumulation rate could reflect changes in yolk production rate per unit mass of intestine and/or changes in intestinal biomass. The hermaphrodite intestine increases in size from day 1 to day 4 as the adult hermaphrodite grows and then decreases due to gut atrophy (10). We, therefore, adjusted YP accumulation rate data for gut volume changes. Relative intestinal volume from day 1 to day 20 was estimated from the diameters of the intestine and intestinal lumen, taking the intestine to be a hollow cylinder, and using data for aging N2 hermaphrodites from our previous study (10). For YP170 and YP115 adjusted accumulation rate, this revealed an early peak followed by an extended period of relatively steady accumulation (Figure 1B; Supplementary Figure 1 [representative SDS-PAGE gel and individual trials]; Supplementary Dataset 1 [raw data]). This supports the presence of open faucet-type yolk synthesis. Peak accumulation rate was earlier for YP170 than YP115, occurring on day 4 and day 7, respectively, implying a difference in VIT-6 synthesis and/or trafficking. For both YP170 and YP115, accumulation ceases abruptly on day 15, followed by a phase of apparent decline in YP levels.

To put these findings into context, adjusted YP170 and YP115 accumulation rate changes were plotted against other parameters of senescence: cumulative YP accumulation, declining pharyngeal pumping rate, intestinal atrophy, and survival (life span; Figure 1C). This shows that YP accumulation is still occurring when the first animals are dying from senescence, and ceases shortly after gut atrophy reaches its peak level. It also shows an approximate correspondence between decline in both the YP accumulation rate and pharyngeal pumping (ie, feeding) rate, possibly due to reduced uptake of food to support yolk biosynthesis. Also notable is the lag between YP
accumulation and intestinal atrophy, which is closely correlated with pseudocoelomic lipoprotein pool (PLP; ie, yolk pool) accumulation (10). This could indicate that gut-to-yolk biomass conversion largely contributes to the later stages of yolk accumulation; a further implication is that the growth of the PLPs occurs particularly during the later stages of intestinal atrophy, possibly due to release of intestinal lipid depots (10).

Cessation of Egg Laying Contributes to Yolk Accumulation

One possible expectation in the source-sink model (Figure 1A) is that during the egg-laying phase, the yolk production rate is set to approximately match the requirements of egg production, and therefore that YP accumulation rate should only rise substantially after days 4–5 (20°C) and sperm depletion. This was true for YP115 but not YP170, whose accumulation rate peaked earlier, on days 3–4 (Figure 1B). This could imply that rate of synthesis of YP170 but not VIT-6 exceeds requirements of egg production.

Another prediction of the source-sink model is that extending the egg-laying period will postpone yolk accumulation whereas blocking egg production will bring it forward. As predicted, extending the egg-laying period by mating with males largely prevented YP170 accumulation (Figure 1D; Supplementary Figure 2), consistent with previous observations of PLPs (10). However, on days 2–4 a slight accumulation of YP was seen, consistent with a slight biosynthetic surplus; mating was previously shown to increase vit messenger RNA (mRNA) levels, and this could be a contributory factor here (21).

The drop in YP accumulation rate after reproduction (Figure 1B) could imply that the presence of sperm increases YP production rate. However, an early peak in YP170 accumulation rate was also seen in spermless fog-2(q71) mutant females (Figure 1E; Supplementary Figure 3), although YP170 initially accumulated faster, probably due to the absence of egg laying in fog-2(q71) females; this is consistent with earlier increases in YP accumulation previously noted in sterile fem-1(bc17) and fem-3(q20gf) mutant hermaphrodites (21). Similarly, blocking yolk transport into oocytes using rme-2 RNAi accelerated YP accumulation (Supplementary Figure 4). Moreover, mating fog-2 females with rf-3(b26) (formerly fer-15) males, which can mate but which produce fertilization-defective sperm, did not alter yolk accumulation rate (Supplementary Figure 5). Again, mating fog-2 females with fog-2 males largely prevented YP accumulation (Supplementary Figure 6).

These results verify that YP accumulation pattern is a function of both YP synthesis and YP disposal by egg laying and confirm that postreproductive hermaphrodites maintain a steady rate of YP accumulation into late adulthood.

Knockdown of YP170 Synthesis Increases YP115/YP88 Levels and Vice Versa

During C. elegans aging, continued yolk production is coupled to intestinal atrophy, and blocking vitellogenin synthesis inhibits intestinal atrophy (10). But is this due to the synthesis of particular vitellogenins or overall vitellogenin synthesis? Combined vit-5 + vit-6 RNAi is sufficient to largely prevent accumulation of all YP species (10). We found that vit-5 RNAi alone largely blocked YP170 accumulation (Figure 2A and B); given the close sequence similarity between vit-3, -4, and -5 (17), it is likely that expression of all three genes is abrogated. vit-5 RNAi also greatly reduces vit-2 mRNA levels (Figure 2C). Unexpectedly, vit-5 RNAi also increased YP115 and YP88 accumulation by up to 44% (Figure 2A and B). Similarly, vit-6 RNAi blocked YP115 and YP88 accumulation but increased YP170 accumulation by up to 35% (Figure 2A and B).

vit-5 RNAi had little effect on vit-6 mRNA and vice versa (Figure 2C). Thus, this reciprocal effect does not involve a mechanism affecting vit gene transcription. This suggests that reducing the abundance of a given vit mRNA species leads to increased translation of other vit mRNA species, perhaps reflecting competition between vit mRNAs for access to translational machinery.

C. elegans hermaphrodites produce copious amounts of yolk, such that as a proportion of total YP levels rise from less than 10% on day 1 of adulthood to almost 40% by day 11 (Figure 2D) (10). As expected, this increase was entirely suppressed by vit-5,-6 RNAi, but due to reciprocal increases in synthesis, vit-5 or vit-6 RNAi alone only slightly reduced overall YP content (Figure 2D). This suggests that vit-5,-6 double RNAi but not vit-5 or vit-6 RNAi should reduce total worm protein content. But surprisingly, not...
even vit-5,-6 RNAi reduced overall protein content (Figure 2E). This implies that other proteins are present in place of vitellogenin after vit-5,-6 RNAi.

To explore this further, we compared Coomassie-stained protein gels of extracts from control and vit-5,-6 RNAi-treated N2 hermaphrodites. This revealed, in the latter, the presence of numerous bands showing an increased abundance of proteins other than vitellogenin (Figure 2F).

**Vitellogenin Synthesis Reduces Levels of Other Intestinal Proteins**

How does vit-5,-6 RNAi increase levels of other proteins? One possibility is that knockdown of all YPs increases synthesis of other intestinal proteins, perhaps due to the absence of monopolization of the protein synthesis machinery in the hermaphrodite intestine by vit mRNAs. To probe this, we tested effects of vit-5, vit-6, or vit-5,-6 RNAi on selected fluorescent reporters of intestinally expressed genes (ftn-1, gcs-1, inx-16, and sod-1) on days 1, 4, and 8 of adulthood. The prediction here was that vit-5,-6 RNAi but not vit-5 or vit-6 RNAi alone would increase reporter expression. However, against expectation, both vit-5 and vit-5,-6 RNAi consistently increased expression of all reporters, whereas vit-6 RNAi reduced fluorescence (Figure 3A and B). vit-5,-6 RNAi did not alter ftn-1, gcs-1, inx-16 or sod-1 mRNA levels (day 1; Figure 3C) supporting the view that vitellogenin synthesis affects levels of other proteins by posttranscriptional mechanisms.

That both vit-5 and vit-5,-6 RNAi, with elevated and reduced levels of YP115/YP88, respectively, similarly increase intestinal reporter expression, suggests that the synthesis of YP170 but not YP115/YP88 reduces levels of other intestinal proteins.

**vit-6 RNAi Enhances Intestinal Atrophy and Shortens Life Span**

Abrogation of yolk accumulation by vit-5,-6 RNAi inhibits intestinal atrophy and extends life span (10). Next, we tested the effects of vit-5 or vit-6 RNAi alone on these traits (20°C). vit-5 RNAi, which increases YP115/YP88 levels, proved to suppress intestinal atrophy to a similar extent as vit-5,-6 RNAi (Figure 4A). vit-5 RNAi caused a modest increase in life span that was statistically significant in 1/3 trials (Figure 4B; Supplementary Table 1; Supplementary Dataset 2), consistent with previous observations (31). Furthermore, vit-5,-6 RNAi more robustly increased life span, both relative to RNAi controls (L4440), as observed previously (10), and to vit-5 RNAi alone (statistically significant in 2/3 trials in each case; Figure 4B; Supplementary Table 1).

Interestingly, vit-6 RNAi, which increases YP170 levels, both enhanced intestinal atrophy (Figure 4A) and reduced life span (Figure 4B; Supplementary Figure 7; Supplementary Table 1). In five trials, mean life span estimates with vit-6 RNAi were lower than controls, and in 2/5 cases the effect was statistically significant, suggesting a modest but real effect on life span. Notably, vit-5 RNAi suppresses the life-shortening effects of vit-6 RNAi on life span (Figure 4B; Supplementary Table 1). Taken together, this implies that production of YP170 but not YP115/YP88 promotes intestinal atrophy and reduces life span (see Discussion section).

vit-5,-6 RNAi also inhibits PLP accumulation (10). However, neither vit-5 RNAi nor vit-6 RNAi alone had a detectable effect on PLP accumulation (Figure 4C), suggesting that high levels of either YP170 or YP115/YP88 are sufficient to assure normal levels of yolk lipid production and/or transport into the body cavity.
Combined with continued yolk production. Our findings confirm the presence of such a source and sink mechanism and also reveal a number of additional details. First, there is an early peak of YP170 accumulation before sperm depletion (Figure 1B and C), suggesting that yolk production exceeds demand during reproduction, at least under replete nutritional conditions. Second, this early peak of yolk production is independent of the presence of sperm, as shown by its occurrence in spermless fog-2 females (Figure 1E). Third, YP115/YP88 levels peak later than those of YP170, suggesting a difference in the synthesis and/or trafficking of VIT-6 (Figure 1B,C). Fourth, there is a relatively steady rate of yolk accumulation in post-reproductive adults, consistent with an unregulated, open faucet mechanism, which ceases abruptly on day 15, perhaps as the result of further intestinal senescence and incipient death (Figure 1B).

We conclude that PLP accumulation, or senescent yolk steatosis, is caused by a combination of post-reproductive continuation of yolk synthesis, and sperm depletion that is a consequence of the pro-tandrous architecture (or bauplan) (34) of the *C. elegans* hermaphrodite germline (ie, because it makes sperm first and then oocytes).

**YP170 Production Drives Intestinal Atrophy and Shortens Life Span**

New features of the mechanisms of senescent pathogenesis in *C. elegans* may be deduced from the effects of selective inhibition of YP170 or YP115/YP88, as follows. Combined *vit*-5,-6 RNAi suppressed gut atrophy and increased life span to a similar degree to *vit*-5 RNAi, despite elevated YP115/YP88 levels in the latter (Figure 5C). By contrast, *vit*-6 RNAi, which increases YP170 levels, increased gut atrophy but not if the increase in YP170 was abrogated by simultaneous *vit*-5 RNAi (Figure 5C). Taken together, this implies that YP170 production or abundance drives intestinal atrophy but that YP115/YP88 does not. This suggests the presence of a senescence-promoting mechanism that specifically couples YP170 synthesis to disappearance of intestinal cell contents. Similarly, effects of RNAi on life span indicate a predominant role of YP170 in life span determination. Moreover, that *vit*-6 RNAi both accelerates gut atrophy and shortens life span provides further evidence that senescent atrophy of the intestine contributes to late-life mortality.

**Possible Causes of Reciprocal Changes in YP Species After vit Gene RNAi**

RNAi knockdown of YP170 caused a reciprocal increase in YP115/YP88 levels and vice versa. This could imply that the intestinal protein biosynthetic machinery is working at full capacity to produce yolk, so that *vit* mRNAs compete with one another for access to ribosomes. Possible reasons for this are hyperabundance of *vit* mRNAs and preferential access of *vit* mRNAs to the translational machinery. We explored both possibilities by the analysis of published RNA sequencing (RNA-seq) and ribosome profiling (ribo-seq) data from a study of whole-worm mRNA extracts from young adult hermaphrodites (40). Examining RNA-seq data, *vit*-6 mRNA was the third most abundant (4,981 reads per kilobase million (RPKM); Supplementary Table 4), and this was exceeded by the sum of mRNAs encoding YP170 (*vit*-1–5, 9,628 RPKM; Supplementary Table 5). Given that these values are for whole-worm extracts, this implies that *vit* mRNAs are very abundant indeed within the intestine.

As an indicator of possible preferential translation of *vit* mRNAs, we tested for high representation of *vit* mRNA in ribo-seq versus mRNA seq data and compared presence of such a source and sink mechanism and also reveal a number of additional details. First, there is an early peak of YP170 accumulation before sperm depletion (Figure 1B and C), suggesting that yolk production exceeds demand during reproduction, at least under replete nutritional conditions. Second, this early peak of yolk production is independent of the presence of sperm, as shown by its occurrence in spermless fog-2 females (Figure 1E). Third, YP115/YP88 levels peak later than those of YP170, suggesting a difference in the synthesis and/or trafficking of VIT-6 (Figure 1B,C). Fourth, there is a relatively steady rate of yolk accumulation in post-reproductive adults, consistent with an unregulated, open faucet mechanism, which ceases abruptly on day 15, perhaps as the result of further intestinal senescence and incipient death (Figure 1B).
The mean values for the 4 vit mRNAs for which data were available with that for the top 20 other most abundant mRNAs (RNA-seq data). This gave values of 1.15 and 1.63, respectively, consistent with possible underrepresentation of vit mRNAs on ribosomes (Supplementary Table 5), although if one excludes the three most abundant ribo-seq mRNAs from this analysis (col-140, eef-1A.1, and rps-7) the latter value is reduced to 1.18. The combination of very high vit mRNA abundance in RNA-seq profiles and possible overrepresentation in ribo-seq data). This gave values of 1.15 and 1.63, respectively, consistent with possible underrepresentation of vit mRNAs on ribosomes (Supplementary Table 5), although if one excludes the three most abundant ribo-seq mRNAs from this analysis (col-140, eef-1A.1, and rps-7) the latter value is reduced to 1.18. The combination of very high vit mRNA abundance in RNA-seq profiles and possible overrepresentation in ribo-seq data suggests that high vitellogenin translation levels are caused by high vit mRNA abundance and that vit mRNA hyperabundance leads to competition between vit mRNA species for access to ribosomes.

However, this scenario does not rule out the presence of other mechanisms enhancing vit mRNA translation rate, whose presence could be masked by very high vit mRNA levels. Preferential access of vit mRNAs to the translational machinery could occur due to mRNA sequence features or by suppression of non-vit mRNA translation. During some forms of viral infection, 5′-cap-dependent translation is suppressed and viral mRNAs are translated via internal ribosome entry site (IRES) sequences (41). However, examination of vit mRNA sequences using the RNAfold web server (42,43) did not reveal any potential IRES sequences. Notably, though, none of the vit mRNAs bear spliced leader sequences (WormBase;www.wormbase.org, release WS267, 2018). One possibility is that the absence of a requirement for trans-splicing enables faster production of mature vit mRNA species.

One hypothesis that we entertained is that translation of vit mRNAs competes with translation of other intestinal proteins, which contributes to intestinal atrophy. Our tests showed that both vit-5 and vit-5,-6 RNAi increased levels of intestinal reporter gene proteins but not their corresponding endogenous mRNAs (Figure 3). This could imply that synthesis of YP170 inhibits translation of other proteins. However, increased reporters could reflect the fact that vit-5 and vit-5,-6 RNAi inhibit gut atrophy (Figure 4A), although increased reporter levels even on day 1 (Figure 3A), long before atrophy appears, argues against this.

Taken together, these results favor the view that high vit mRNA abundance rather than preferential translation mechanisms leads to competition with other mRNAs for access to translational machinery. However, they also suggest a weaker competitive effect of vit-6 mRNA (given that YP170 synthesis specifically is coupled to intestinal atrophy).

**Effects of Vitellogenins on Oxidative Stress Resistance and Life Span**

vit-5 RNAi increases YP115/YP88 levels and causes Oxr, and both effects are suppressed by vit-6 RNAi (Figure 2A and B; Figure 5A and B). This is consistent with a previously suggested antioxidant role for YP115 (32). We previously described an age increase in Oxr (t-BOOH) in N2 hermaphrodites (44); one possibility is that VIT-6 accumulation contributes to this age increase in Oxr.

The early, influential theory that reactive oxygen species are a major cause of aging (45,46) suggests that vitellogenins should protect against aging. In fact, knockdown of vitellogenin expression can increase life span in *C. elegans* (10,31) (this study) and in the lubber grasshopper, *Romalea microptera* (47), but reduce it in the honeybee, *Apis mellifera* (48). Here, we show that nematodes subjected to vit-6 RNAi are Oxr but shorter-lived than non-Oxr vit-5,-6 and vit-5 RNAi populations (Figure 4B; Figure 5A and B), that is, effects of vitellogenins on Oxr and longevity can be uncoupled. This is consistent with numerous findings arguing against the view that reactive oxygen species are a major cause of senescence in *C. elegans* (28,49,50). However, it remains possible that reactive oxygen species damage contributes to some senescent pathologies that do not limit *C. elegans* life span under standard culture conditions.

**Later Vitellogenesis: Alternative Models of Antagonistic Pleiotropy**

Why after sperm depletion do *C. elegans* continue to synthesize yolk, even causing intestinal pathology to do this? We suggest two possibilities, both consistent with the evolutionary principle of antagonistic pleiotropy. This principle postulates that genes can exert a variety of effects on phenotype throughout life and that earlier effects will have greater impact on fitness due to smaller relative reproductive output at later ages. Consequently, selection may favor alleles with greater early-life fitness benefits even if they cause pathology in later life (ie, senescence) (1).
The first possibility is that continued yolk production represents nonadaptive run-on of processes that contribute to fitness in earlier life (8). The absence of a mechanism to turn yolk production off could reflect the lack of any selective advantage that such an off switch would confer. Such a mechanism is consistent with Blagosklonny’s quasi-program model of antagonistic pleiotropy action, where late-life action of wild-type genes directly promote pathogenetic biological programs (rather than indirectly through effects on damage accumulation) (1,2). Quasi-programs are also a major cause of uterine tumor formation in aging C. elegans (4).

A second possibility is that continued yolk production contributes to fitness by some mechanisms as yet unidentified, for example, by increasing reproductive success after later-life mating. Such a mechanism would represent a direct reproductive cost comparable, for example, to costs of lactation in female mammals, which include bone atrophy due to release of bone calcium for milk production (51). Either way, understanding the mechanisms involved should be informative with respect to the identification of general principles of senescent pathophysiology.

Supplementary Material
Supplementary data are available at The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences online.

Funding
This work was supported by el Instituto para la Formación y Aprovechamiento de Recursos Humanos, y la Secretaría Nacional de Ciencia, Tecnología e Innovación, Panamá (Y.G.), Naresuan University, Thailand (T.S.), and a Wellcome Trust Award (098565/Z/12/Z to D.G.).

Acknowledgements
We wish to thank members of the Gems laboratory for useful discussion. We thank the Caenorhabditis Genetics Center, which is funded by the National Center for Research Resources of National Institutes of Health, for providing many of the strains used in this study.

Conflict of Interest
The authors declare no conflicts of interests.

References
1. Williams GC. Pleiotropy, natural selection and the evolution of senescence. Evolution. 1957;11:398–411. doi:10.2307/2406060
2. Blagosklonny MV. Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition. Cell. 2006;5:2087–2102. doi:10.1016/j.cec.2006.03.3288
3. Blagosklonny MV. Paradoxes of aging. Cell. 2007;6:2977–3003. doi:10.1016/j.cec.2007.06.001
4. Wang H, Zhao Y, Escarza M, et al. A parthenogenetic quasi-program causes teratoma-like tumors during aging in wild-type C. elegans. NPG Aging Mech Disease. 2018;4:6. doi:10.1038/s41514-018-0025-3
5. Gems D. What is an anti-aging treatment? Exp Gerontol. 2014;58:14–18. doi:10.1016/j.exger.2014.07.003
6. Gems D, de la Guardia Y. Alternative perspectives on aging in Caenorhabditis elegans: reactive oxygen species or hyperfunction? Antioxid Redox Signal. 2013;19:321–329. doi:10.1089/ars.2012.4840
7. Garigan D, Hsu AL, Fraser AG, Kamath RS, Ahringer J, Kenyon C. Genetic analysis of tissue aging in Caenorhabditis elegans: a role for heat-shock factor and bacterial proliferation. Genetics. 2002;161:1101–1112.
8. Herndon LA, Schmeissner PJ, Dudaronek JM, et al. Stochastic and genetic factors influence tissue-specific decline in aging C. elegans. Nature. 2002;419:808–814. doi:10.1038/nature01135
9. Palikaras K, Mari M, Petanidou B, Pasparaki A, Filippidis G, Tavernarakis N. Ectopic fat deposition contributes to age-associated pathology in Caenorhabditis elegans. J Lipid Res. 2017;58:72–80. doi:10.1194/jlr.M069385
10. Ezcurra M, Benedetto A, Sornda T, et al. C. elegans eats its own intestine to make yolk leading to multiple senescent pathologies. Curr Biol. 2018;28:2554–2556. doi:10.1016/j.cub.2018.06.035
11. Van Rompay L, Borgehraef C, Beets I, Caers J, Temmerman L. New genetic regulators question relevance of abundant yolk protein production in C. elegans. Sci Rep. 2015;5:16381. doi:10.1038/srep16381
12. Baker ME. Invertebrate vitellogenin is homologous to human von Willebrand factor. Biochem J. 1988;255:1035–1060. doi:10.1042/bj2551035
13. Baker ME. Is vitellogenin an ancestor of apolipoprotein B-100 of human low-density lipoprotein and human lipoprotein lipase? Biochem J. 1988;255:1057–1060. doi:10.1042/bj2551057
14. Maryash V, Geier C, Henske A, et al. Distribution and transport of cholesterol in Caenorhabditis elegans. Mol Biol Cell. 2001;12:1725–1736. doi:10.1091/mbc.12.6.1725
15. Grant B, Hirsh D. Receptor-mediated endocytosis in the Caenorhabditis elegans oocyte. Mol Biol Cell. 1999;10:4311–4326. doi:10.1091/mbc.10.12.4311
16. Kimble J, Sharrock WJ. Tissue-specific synthesis of yolk proteins in Caenorhabditis elegans. Dev Biol. 1983;96:189–196. doi:10.1016/0012-1606(83)90322–6
17. Spier J, Blumenthal T. The Caenorhabditis elegans vitellogenin gene family includes a gene encoding a distantly related protein. Mol Biol Cell. 1995;5:2495–2501. doi:10.1128/MCB.5.10.2495
18. Spier J, Denison K, Kirtland S, Cane J, Blumenthal T. The C. elegans vitellogenin genes: short sequence repeats in the promoter regions and homology to the vertebrate genes. Nucleic Acids Res. 1983;13:5283–5295.
19. The C. elegans Sequencing Consortium. Genome sequence of the nematode C. elegans: a platform for investigating biology. Science. 1998;282:1239–2012. doi:10.1126/science.282.5396.2012
20. McGee MD, Weber D, Day N, et al. Loss of intestinal nuclei and intestinal integrity in aging C. elegans. Aging Cell. 2011;10:699–710. doi:10.1111/j.1474-9726.2011.00713.x
21. DePina AS, Iser WB, Park SS, Maudsley S, Wilson MA, Wolcock CA. Regulation of Caenorhabditis elegans vitellogenesis by DAF-2/Ins through separable transcriptional and posttranscriptional mechanisms. BMC Physiol. 2011;11:11. doi:10.1186/1472-6793-11-11
22. de la Guardia Y, Gilliat AE, Hellberg J, Bennert P, Cabreiro F, Gems D. Run-on of germline apoptosis promotes gonad senescence in C. elegans. Oncotarget. 2016;7:39082–39096. doi:10.18632/oncotarget.9681
23. Libina N, Berman JR, Kenyon C. Tissue-specific activities of C. elegans DAF-16 in the regulation of lifespan. Cell. 2003;113:489–502. doi:10.1016/S0092-8674(03)00889-4
24. Budovskyaya YV, Wu K, Southworth LK, et al. An elt-3/elt-5elt-6 GATA transcription circuit guides aging in C. elegans. Cell. 2008;134:291–303. doi:10.1016/j.cell.2008.05.044
25. Brenner S. The genetics of Caenorhabditis elegans. Genetics. 1974;77:1–94.
26. Kamath RS, Martinez-Campos M, Zipperlen P, Fraser AG, Ahringer J. Effectiveness of specific RNA-mediated interference through ingested double-stranded RNA in Caenorhabditis elegans. Genome Biol. 2001;2:RESEARCH0002. doi:10.1186/9636-2001-2-research002
27. Gems D, Riddle DL. Defining wild-type life span in Caenorhabditis elegans. J Gerontol A Biol Sci Med Sci. 2000;55:B215–B219. doi:10.1093/gerona/55.5.B215
28. Doonan R, McElwee JJ, Matthijssens F, et al. Against the oxidative damage theory of aging: superoxide dismutases protect against oxidative stress but have little or no effect on life span in Caenorhabditis elegans. Genes Dev. 2008;22:3236–3241. doi:10.1101/gad.504808
29. Ackerman D, Gems D. Insulin/GF-1 and hypoxia signaling act in concert to regulate iron homeostasis in Caenorhabditis elegans. PLoS Genet. 2012;8:e1002498. doi:10.1371/journal.pgen.1002498
30. Hoogewijs D, Houthoofd K, Matthijssens F, Vanesompele J, Vanfleteren JR. Selection and validation of a set of reliable reference genes for quantitative sod gene expression analysis in C. elegans. BMC Mol Biol. 2008;9:9. doi: 10.1186/1471-2199-9-9

31. Murphy CT, McCarroll SA, Bargmann CI, et al. Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature. 2003;424:277–283. doi: 10.1038/nature01789

32. Nakamura A, Yasuda K, Adachi H, Sakurai Y, Ishii N, Goto S. Vitellogenin-6 is a major carbonylated protein in aged nematode, Caenorhabditis elegans. Biochem Biophys Res Commun. 1999;264:580–583. doi: 10.1006/bbrc.1999.1549

33. Seehuus SC, Norberg K, Gimsa U, Krekling T, Amdam GV. Reproductive protein protects functionally sterile honey bee workers from oxidative stress. Proc Natl Acad Sci USA. 2006;103:962–967. doi: 10.1073/pnas.0502681103

34. Gould SJ, Lewontin RC. The spandrels of San Marco and the Panglossian paradigm: a critique of the adaptationist programme. Proc R Soc Lond B Biol Sci. 1979;205:581–598. doi: 10.1098/rspb.1979.0086

35. Friedman DB, Johnson TE. A mutation in the age-1 gene in Caenorhabditis elegans lengthens life and reduces hermaphrodite fertility. Genetics. 1988;118:75–86.

36. Kenyon C, Chang J, Gensch E, Rudner A, Tabtiang R. A C. elegans mutant that lives twice as long as wild type. Nature. 1993;366:461–464. doi: 10.1038/366461a0

37. McElwee J, Bub K, Thomas JH. Transcriptional outputs of the Caenorhabditis elegans forkhead protein DAF-16. Aging Cell. 2003;2:111–121. doi: 10.1046/j.1474-9728.2003.00043.x

38. Depuydt G, Xie F, Petyuk VA, et al. Reduced insulin/insulin-like growth factor-1 signaling and dietary restriction inhibit translation but preserve muscle mass in Caenorhabditis elegans. Mol Cell Proteomics. 2013;12:3624–3639. doi: 10.1074/mcp.M113.027383

39. Essers P, Nonneken J, Goos Y, et al. A long noncoding RNA on the ribosome is required for lifespan extension. Cell Rep. 2015;10:339–343. doi:10.1016/j.celrep.2014.12.029

40. Arnold A, Rahman MM, Lee MC, et al. Functional characterization of C. elegans Y-box-binding proteins reveals tissue-specific functions and a critical role in the formation of polyosomes. Nucleic Acids Res. 2014;42:13353–13369. doi: 10.1093/nar/gku1077

41. Reineke LC, Lloyd RE. Animal virus schemes for translation dominance. Curr Opin Virol. 2011;1:363–372. doi: 10.1016/j.coviro.2011.10.009

42. Gruber AR, Lorenz R, Bernhart SH, Hofacker IL. The Vienna RNA websuite. Nucleic Acids Res. 2008;36(Web Server issue):W70–W74. doi: 10.1093/nar/gkn188

43. Lorenz R, Bernhart SH, Höner Zu Siederdissen C, et al. ViennaRNA Package 2.0. Algorihtms Mol Biol. 2011;6:26. doi: 10.1186/1748-7188-6-26

44. Benedetto A, Bambade T, Au C, et al. LFASS: label-free automated survival scoring for high-throughput nematode assays. BioRxiv. 2017. doi:10.1101/195347

45. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol. 1956;11:298–300. doi: 10.1093/geronj/11.3.298

46. Beckman KB, Ames BN. The free radical theory of aging matures. Physiol Rev. 1998;78:547–581. doi: 10.1152/physrev.1998.78.2.547

47. Tetlak AG, Burnett JB, Hahn DA, Hatle JD. Vitellogenin-RNAi and ovariectomy each increase lifespan, increase protein storage, and decrease feeding, but are not additive in grasshoppers. BioGerontology. 2015;16:761–774. doi: 10.1007/s10522-015-9599-3

48. Nelson CM, Bile KE, Fondrk MK, Page RE, Amdam GV. The gene vitellogenin has multiple coordinating effects on social organization. PLoS Biol. 2007;5:e262. doi: 10.1371/journal.pbio.0050062

49. Keaney M, Matthijssens F, Sharpe M, Vanfleteren J, Gems D. Superoxide dismutase mimetics elevate superoxide dismutase activity in vivo but do not retard aging in the nematode Caenorhabditis elegans. Free Radic Biol Med. 2004;37:239–250. doi: 10.1016/j.freeradbiomed.2004.04.005

50. Van Raamsdonk JM, Hekimi S. Reactive oxygen species and aging in Caenorhabditis elegans: causal or casual relationship? Antioxid Redox Signal. 2010;13:1911–1953. doi: 10.1089/ars.2010.3215

51. Speakman JR. The physiological costs of reproduction in small mammals. Philos Trans R Soc Lond B Biol Sci. 2008;363:375–398. doi: 10.1098/rstb.2007.2145